Over 150 people marked the 500th participant in the ACT to be enrolled in the healthy ageing study, ASPREE (ASPirin in Reducing Events in the Elderly) at a morning tea in Canberra today. ASPREE, the largest ever primary prevention aspirin study in Australians aged 70 and over, is investigating whether aspirin can delay or prevent the…
Details
We’d love you to follow our progress on @ASPREE_aus What is twitter? It’s an online service that allows people to send messages limited to 140 characters per entry. The summary-like messages are instant and sent to those who follow you. Millions of people around the world have a twitter account. While we will be tweeting about ASPREE events…
Details
Senior ASPREE investigator, Professor Mark Nelson says a recent paper that links taking NSAID (Non Steroidal Anti-inflammatory Drugs) to a decrease in the risk of developing skin cancer underscores the importance of the ASPREE study. “We welcome the findings of this study as the possibility of aspirin having cancer preventing properties is one of the rationales…
Details
Popular morning radio personalities Ross and John on Melbourne radio station 3AW, interviewed Prof Andrew Tonkin, ASPREE senior investigator and Head of Cardiovascular Research Unit, Monash University about aspirin and the ASPREE trial. Hear Andrew discuss the pros and cons of aspirin and what the ASPREE study is really about. Click here to listen (run time…
Details
Recently published research suggesting aspirin could be used to combat cancer only reinforces the need for more in depth analysis, one of the world’s foremost aspirin experts has said. Principal Investigator to ASPREE (ASPirin in Reducing Events in the Elderly) Professor John McNeil said the research, conducted by a team at the University of Oxford…
DetailsResearch findings by Rothwell et al, (two in ‘The Lancet’ and one in ‘The Lancet Oncology’) to hit the media today are suggesting that daily aspirin can be used to help prevent and possibly treat cancer. Professor John McNeil, Principal Investigator of the ASPREE study in Australia puts these papers in context: The new research…
Details
“Recent headlines that ‘a daily dose of aspirin may do more harm than good’ have been described by one of Australia’s foremost experts on the drug as crude, sensational and likely to cause undue concern among Australians….” Read Professor Mark Nelson’s full interview published in the Australian Ageing Agenda in response to a UK aspirin study published in the Archives of Internal Medicine, :
Earlier this week more than 250 people marked the first anniversary of the Monash University-led healthy ageing study ASPREE (ASPirin in Reducing Events in the Elderly) at separate functions in Ballarat and Traralgon, Gippsland. The events were also a time to celebrate the recruitment of the 250th ASPREE participant from each region. ASPREE, the largest…
Details
Celine Foenander from the mornings program interviews Dr Woods, Executive Officer for ASPREE about the study, the potential for an ASPREE regional site in Traralgon and whether aspirin could be used as preventative treatment in certain types of cancer. ASPREE would like to thank ABC Gippsland radio for permission to replay this interview on…
Details
MEDIA RELEASE Australia’s largest clinical trial to test benefits of aspirin Researchers at Monash University and the United States-based Berman Center for Outcomes & Clinical Research will lead an international clinical trial to test whether taking aspirin contributes to good health in the elderly. The trial, ASPirin in Reducing Events in the Elderly (ASPREE), has…
Details© 2019 All Rights Reserved. • Monash University, Department of Epidemiology and Preventive Medicine | Disclaimer & Privacy